X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3733) 3733
Publication (363) 363
Book Review (61) 61
Book Chapter (11) 11
Conference Proceeding (6) 6
Dissertation (5) 5
Magazine Article (3) 3
Data Set (1) 1
Paper (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
irinotecan (2777) 2777
humans (2733) 2733
index medicus (1908) 1908
oncology (1841) 1841
pharmacology & pharmacy (1738) 1738
camptothecin - analogs & derivatives (1623) 1623
female (1280) 1280
male (1232) 1232
chemotherapy (1184) 1184
cancer (1082) 1082
animals (931) 931
middle aged (906) 906
aged (850) 850
colorectal cancer (779) 779
colorectal neoplasms - drug therapy (771) 771
adult (755) 755
antineoplastic combined chemotherapy protocols - therapeutic use (738) 738
camptothecin - administration & dosage (719) 719
camptothecin - pharmacology (578) 578
oxaliplatin (536) 536
fluorouracil (525) 525
treatment outcome (504) 504
cpt-11 (471) 471
colorectal neoplasms - pathology (470) 470
mice (462) 462
cell line, tumor (431) 431
pharmacokinetics (427) 427
pharmacology/toxicology (427) 427
leucovorin (426) 426
medicine & public health (422) 422
antineoplastic agents - therapeutic use (419) 419
antineoplastic agents - pharmacology (415) 415
bevacizumab (414) 414
antineoplastic combined chemotherapy protocols - adverse effects (407) 407
care and treatment (388) 388
camptothecin - therapeutic use (380) 380
research (378) 378
1st-line treatment (376) 376
camptothecin - pharmacokinetics (367) 367
camptothecin - adverse effects (360) 360
5-fluorouracil (358) 358
metastasis (358) 358
camptothecin (356) 356
metastatic colorectal-cancer (354) 354
toxicity (348) 348
tumors (344) 344
sn-38 (333) 333
neoplasms - drug therapy (328) 328
therapy (323) 323
fluorouracil - administration & dosage (322) 322
antineoplastic agents (318) 318
cancer research (315) 315
dose-response relationship, drug (308) 308
analysis (300) 300
trial (300) 300
cisplatin (294) 294
antimitotic agents (290) 290
cetuximab (289) 289
combination (283) 283
drug therapy (283) 283
expression (282) 282
pharmacology (280) 280
neoplasm metastasis (276) 276
antineoplastic combined chemotherapy protocols - administration & dosage (273) 273
plus irinotecan (272) 272
phase-ii (267) 267
antineoplastic agents, phytogenic - pharmacology (263) 263
colorectal-cancer (261) 261
aged, 80 and over (257) 257
apoptosis (244) 244
disease-free survival (243) 243
cell lung-cancer (241) 241
clinical trials (237) 237
phase-ii trial (237) 237
survival (236) 236
drug administration schedule (228) 228
cancer therapies (227) 227
colorectal neoplasms - genetics (224) 224
organoplatinum compounds - administration & dosage (224) 224
antineoplastic agents - administration & dosage (214) 214
drug resistance, neoplasm (212) 212
metabolism (209) 209
phase-i (209) 209
glucuronosyltransferase - genetics (205) 205
leucovorin - administration & dosage (202) 202
antineoplastic agents, phytogenic - administration & dosage (201) 201
antineoplastic agents, phytogenic - pharmacokinetics (201) 201
article (199) 199
rats (199) 199
patients (196) 196
lung neoplasms - drug therapy (192) 192
drugs (190) 190
antibodies, monoclonal, humanized (185) 185
health aspects (185) 185
irinotecan cpt-11 (184) 184
pharmacogenetics (184) 184
antineoplastic agents - adverse effects (182) 182
survival analysis (182) 182
xenograft model antitumor assays (182) 182
antitumor-activity (179) 179
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3700) 3700
Japanese (85) 85
Chinese (14) 14
French (9) 9
Spanish (9) 9
German (3) 3
Dutch (1) 1
Korean (1) 1
Polish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Investigational New Drugs, ISSN 0167-6997, 6/2012, Volume 30, Issue 3, pp. 1248 - 1256
This study sought to measure the degree of synergy induced by specific small molecule inhibitors of DNA-PK [NU7026 and IC486241 (ICC)], a major component of... 
Anthracyclines | DNA-PK | Medicine & Public Health | Homologous recombination | Non-homologous end joining | Oncology | DNA-damage | Breast cancer | Pharmacology/Toxicology | DNA-repair | Drug synergism | PHOSPHORYLATION | DEPENDENT PROTEIN-KINASE | DOUBLE-STRAND BREAKS | OXALIPLATIN | DAMAGE | REPAIR | ONCOLOGY | COLORECTAL-CANCER | COMBINATION CHEMOTHERAPY | PHARMACOLOGY & PHARMACY | ATM | CYTOTOXICITY | DNA-Activated Protein Kinase - antagonists & inhibitors | Cell Survival - drug effects | HCT116 Cells | Humans | Morpholines - pharmacology | Cisplatin - pharmacology | Comet Assay | Organoplatinum Compounds - pharmacology | Drug Synergism | HT29 Cells | Topoisomerase I Inhibitors - pharmacology | Cell Cycle Checkpoints - drug effects | Colonic Neoplasms - pathology | Acridones - pharmacology | Antineoplastic Agents - pharmacology | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Chromones - pharmacology | Camptothecin - pharmacology | Camptothecin - analogs & derivatives | Antimitotic agents | Complications and side effects | Colon cancer | DNA damage | Dosage and administration | Research | Antineoplastic agents | Drug therapy | Studies | Pharmacology | Deoxyribonucleic acid--DNA | Colorectal cancer | Drugs | Flow cytometry | Phosphorylation | Data processing | Tumor cell lines | Synergism | Comet assay | Western blotting | Homologous recombination repair | Irinotecan | Rad51 protein | DNA-dependent protein kinase | homologous recombination | Cell cycle | oxaliplatin
Journal Article
Nature Medicine, ISSN 1078-8956, 06/2016, Volume 22, Issue 6, pp. 624 - 631
Cetuximab is a monoclonal antibody that is effective in the treatment of metastatic colorectal cancer (mCRC). Cetuximab blocks epidermal growth factor receptor... 
MEDICINE, RESEARCH & EXPERIMENTAL | 1ST-LINE TREATMENT | PLUS IRINOTECAN | EFFICACY | BIOCHEMISTRY & MOLECULAR BIOLOGY | METASTATIC COLORECTAL-CANCER | CELL BIOLOGY | CALRETICULIN EXPOSURE | COLON-CANCER | BRAF MUTATION | POOLED ANALYSIS | ENDOPLASMIC-RETICULUM | KRAS | Leucovorin - administration & dosage | Proto-Oncogene Proteins p21(ras) - genetics | Colorectal Neoplasms - genetics | Dendritic Cells - immunology | Humans | Cell Death - immunology | X-Box Binding Protein 1 - drug effects | Endoplasmic Reticulum Stress - immunology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Fluorouracil - administration & dosage | Calreticulin - drug effects | Calreticulin - metabolism | Camptothecin - administration & dosage | Dendritic Cells - drug effects | Indoles - pharmacology | Pyrimidinones - pharmacology | Antineoplastic Agents - pharmacology | Cell Death - drug effects | Camptothecin - analogs & derivatives | Disease Models, Animal | Phagocytosis - drug effects | X-Box Binding Protein 1 - immunology | Endoplasmic Reticulum Stress - drug effects | Antibodies, Monoclonal - pharmacology | HCT116 Cells | Phagocytosis - immunology | Cetuximab - pharmacology | Sulfonamides - pharmacology | Unfolded Protein Response | HT29 Cells | Animals | Colorectal Neoplasms - immunology | Proto-Oncogene Proteins B-raf - genetics | X-Box Binding Protein 1 - metabolism | Cell Line, Tumor | Mice | Pyridones - pharmacology | Physiological aspects | Genetic aspects | Immune response | Research | Drug therapy | Colorectal cancer | Care and treatment | Usage | Chemotherapy | Epidermal growth factor | Cell death | Analysis | Endoplasmic reticulum | Cancer | Monoclonal antibodies | Apoptosis | Immune system
Journal Article
British Journal of Cancer, ISSN 0007-0920, 11/2018, Volume 119, Issue 10, pp. 1233 - 1243
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 12/2014, Volume 74, Issue 6, pp. 1125 - 1137
The aim of the study was to demonstrate the activity of etirinotecan pegol, a polymer conjugate of irinotecan, in multiple human tumor models and to establish... 
Medicine & Public Health | SN38 | Anticancer activity | Etirinotecan pegol | Oncology | Cancer Research | Pharmacology/Toxicology | Pharmacokinetics | Topoisomerase 1 inhibition | XENOGRAFT MODELS | IRINOTECAN CPT-11 | SOLID TUMORS | MULTICENTER PHASE-II | ANTICANCER AGENTS | OVARIAN-CANCER | METASTATIC COLORECTAL-CANCER | CELL LUNG-CANCER | BREAST-CANCER | 2 SCHEDULES | ONCOLOGY | PHARMACOLOGY & PHARMACY | Species Specificity | Humans | Male | Antineoplastic Agents - administration & dosage | Heterocyclic Compounds, 4 or More Rings - pharmacology | Neoplasms, Experimental - pathology | Topoisomerase I Inhibitors - pharmacology | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Camptothecin - analogs & derivatives | Polyethylene Glycols - pharmacology | Heterocyclic Compounds, 4 or More Rings - administration & dosage | Topoisomerase I Inhibitors - pharmacokinetics | Topoisomerase I Inhibitors - administration & dosage | Polyethylene Glycols - pharmacokinetics | Rats | Treatment Outcome | Mice, SCID | Rats, Sprague-Dawley | Polyethylene Glycols - administration & dosage | Xenograft Model Antitumor Assays | Animals | Heterocyclic Compounds, 4 or More Rings - pharmacokinetics | Mice, Nude | Dogs | Mice | Camptothecin - pharmacology | Neoplasms, Experimental - drug therapy | Plasma physics | Polymers | Analysis | Lung cancer | Cancer | Original
Journal Article
Pharmaceutical Research, ISSN 0724-8741, 12/2018, Volume 35, Issue 12, pp. 1 - 10
The organic cation transporters (OCTs) and multidrug and toxin extrusions (MATEs) together are regarded as an organic cation transport system critical to the... 
Biochemistry, general | Biomedicine | irinotecan | Pharmacy | Medical Law | organic cation transporters | Pharmacology/Toxicology | Biomedical Engineering and Bioengineering | drug and drug interactions | morphine | DRUG | METFORMIN | TOXIN | GENETIC-VARIANTS | CHEMISTRY, MULTIDISCIPLINARY | POLYMORPHISMS | PAIN | PHARMACOKINETICS | MATES | SUBSTRATE | MULTIDRUG | PHARMACOLOGY & PHARMACY | Ondansetron - pharmacology | Humans | Organic Cation Transporter 2 - antagonists & inhibitors | Organic Cation Transporter 2 - metabolism | Organic Cation Transporter 1 - metabolism | Tissue Distribution | Drug Interactions | HEK293 Cells | Ondansetron - metabolism | Irinotecan - pharmacology | Fluoxetine - pharmacology | Organic Cation Transport Proteins - metabolism | Mice, Inbred C57BL | Amitriptyline - metabolism | Morphine - metabolism | Irinotecan - metabolism | Verapamil - pharmacology | Animals | Imipramine - metabolism | Fluoxetine - metabolism | Organic Cation Transporter 1 - antagonists & inhibitors | Narcotics - metabolism | Amitriptyline - pharmacology | Imipramine - pharmacology | Verapamil - metabolism | Antidepressants | Morphine | Drug interactions | Drugs | Organic cation transporter | Amitriptyline | Kidneys | Fluoxetine | Oct-2 protein | Substrates | Irinotecan | Imipramine | Verapamil | Extrusion | Mice | In vivo methods and tests | Drug interaction | Cations | Inhibition | Transporter
Journal Article
Journal Article
Cancer Biology & Therapy, ISSN 1538-4047, 08/2011, Volume 12, Issue 3, pp. 229 - 238
Quinacrine has been widely explored in treatment of malaria, giardiasis, and rheumatic diseases. We find that quinacrine stabilizes p53 and induces... 
Binding | Proteins | Landes | Calcium | Bioscience | Biology | Cell | Cycle | Cancer | Organogenesis | Tumor xenograft | Quinacrine | TRAIL | Sorafenib | Hepatocellular carcinoma | Apoptosis | p53 | sorafenib | INDUCED APOPTOSIS | tumor xenograft | apoptosis | DEATH | AUTOPHAGY | quinacrine | THERAPY | ONCOLOGY | PLEURAL EFFUSIONS | DRUGS | NF-KAPPA-B | hepatocellular carcinoma | Niacinamide - analogs & derivatives | Microtubule-Associated Proteins - metabolism | Humans | Cytoplasm - metabolism | Deoxycytidine - pharmacology | Phenylurea Compounds | Receptors, TNF-Related Apoptosis-Inducing Ligand - metabolism | Proto-Oncogene Proteins c-bcl-2 - metabolism | Benzenesulfonates - pharmacology | Genes, p53 | Quinacrine - pharmacology | Carcinoma, Hepatocellular - drug therapy | Cell Nucleus - metabolism | TNF-Related Apoptosis-Inducing Ligand - pharmacology | Female | Liver Neoplasms - pathology | Antineoplastic Agents - pharmacology | Cell Death - drug effects | Tumor Cells, Cultured | Camptothecin - analogs & derivatives | Liver Neoplasms - drug therapy | Etoposide - pharmacology | Drug Synergism | Xenograft Model Antitumor Assays | Irinotecan | Animals | Myeloid Cell Leukemia Sequence 1 Protein | Carcinoma, Hepatocellular - pathology | Fluorouracil - pharmacology | Mice | Pyridines - pharmacology | RNA, Small Interfering | Cell Nucleus - drug effects | Camptothecin - pharmacology | Cytoplasm - drug effects | Deoxycytidine - analogs & derivatives | Doxorubicin - pharmacology | Quinacrine - pharmacokinetics
Journal Article
Basic & Clinical Pharmacology & Toxicology, ISSN 1742-7835, 10/2018, Volume 123, Issue 4, pp. 443 - 451
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 01/2019, Volume 59, Issue 1, pp. 20 - 34
Journal Article